More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...

Investing.com -- Tvardi Therapeutics (NASDAQ:TVRD) stock plunged 30% after the company reported disappointing preliminary data from its Phase 2 REVERT trial evaluating TTI-101 in idiopathic pulmonary ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

Sebi proposes key changes on IPF, tightening norms for exclusively listed companies, proposals include Ease of Doing Business for Exchanges. The Securities and Exchange Board of India (Sebi) has ...

Actinomyces and CCL11 are identified as significant contributors to idiopathic pulmonary fibrosis through the gut-lung axis. Mendelian randomization implicated 12 gut microbiota taxa and 8 ...

Inventor Samuel F. B. Morse spent summers at his Locust Grove Estate in New York's Hudson Valley. The 14,000-square-foot Italianate villa, built in 1852, has 45 rooms over six floors. It was purchased ...

The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...

Official support for free-threaded Python, and free-threaded improvements Python’s free-threaded build promises true parallelism for threads in Python programs by removing the Global Interpreter Lock ...

The FDA has approved Boehringer Ingelheim's nerandomilast as a treatment for idiopathic pulmonary fibrosis (IPF), giving the company a successor to its blockbuster therapy Ofev. Phosphodiesterase (PDE ...

Every time Talia publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...